

Product datasheet for **AP31753PU-N**

galectin 9 (LGALS9) Rabbit Polyclonal Antibody

Product data:

Product Type:	Primary Antibodies
Applications:	ELISA, IF, IHC, WB
Recommended Dilution:	ELISA: 1/1000. Immunofluorescence: 1/100 - 1/500. Immunohistochemistry on Paraffin Sections: 1/100. Western Blot: 1/500 - 1/1000.
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Isotype:	IgG
Clonality:	Polyclonal
Immunogen:	Synthetic peptide from Human LEG9. Epitope: aa51-100
Specificity:	This antibody detects endogenous levels of total LEG9 protein.
Formulation:	PBS (without Mg ²⁺ , Ca ²⁺), pH 7.4, 150 mM Sodium Chloride, 0.02% Sodium Azide and 50% Glycerol State: Aff - Purified State: Liquid purified Ig fraction
Concentration:	lot specific
Purification:	Immunoaffinity Chromatography
Conjugation:	Unconjugated
Storage:	Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Gene Name:	galectin 9
Database Link:	Entrez Gene 16859 Mouse Entrez Gene 25476 Rat Entrez Gene 3965 Human O00182



[View online »](#)


Background:

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS9 is an S-type lectin. This galectin is strongly overexpressed in Hodgkin's disease tissue and it might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its consistently associated immunodeficiency. The protein has N- and C-terminal carbohydrate-binding domains connected by a link peptide. Two isoforms (long and short) exist.


Synonyms:

LGALS9, Galectin9, HOM-HD-21, Ecalectin


Product images:



Western blot analysis of extracts from HepG2 cells, using LEG9 Antibody. The lane on the right is treated with the synthesized peptide.



Human Thymus: Formalin-Fixed, Paraffin-Embedded (FFPE)



Immunofluorescence analysis of NIH-3T3 cells, using LEG9 Antibody. The picture on the right is treated with the synthesized peptide.